Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Update

5 Jan 2017 07:00

RNS Number : 3773T
Persimmon PLC
05 January 2017
 

 

 

TRADING UPDATE - 5 JANUARY 2017

 

 

Persimmon plc announces the following update ahead of its Final Results for the year ended 31 December 2016, which will be released on 27 February 2017.

 

Revenues for 2016 of £3.14bn were 8% higher than the prior year (2015: £2.90bn) with legal completion volumes increasing by 599 new homes to 15,171 (2015: 14,572). The Group's average selling price increased by 4% to c. £206,700 (2015: £199,127).

 

Sales reservations through the autumn season were strong with healthy customer demand for new homes. Buying a new-build home remains a compelling choice supported by competitive mortgage offers which continue to make a new home purchase very affordable. The Group's private sales rate for the second half of the year was 15% ahead of the prior year and second half legal completion volumes of 7,933 were 695 stronger than for the first half of the year (H1: 7,238).

 

We have continued to focus on disciplined high quality growth to achieve sustainable market share in our regional markets. The two new house building businesses we opened at the start of 2016 based in Perth, Scotland and Launceston, Cornwall have made good progress delivering over 650 new homes in their first year of operation. On 2 January 2017 we launched a further new business based in Mansfield, north of Nottingham, to support the delivery of increased volumes of new homes in this regional market. The value of our forward sales at 31 December 2016 of c. £1,230m is 12% ahead of the prior year (2015: £1,103m).

 

The Group successfully opened 255 new development sites across the UK during the year and is building on all sites which have an implementable planning consent. We expect our gross margin in the second half will have improved further due to a combination of the continued reduction in our land cost recoveries associated with opening new sites, and the continued strong control over development costs.

 

During the year we acquired c. 18,700 plots of new land in 83 locations with good deferred terms. We continue to see good opportunities to acquire additional land whilst remaining mindful of the risks associated with the uncertainty arising from the UK's decision to leave the EU. We continue to work hard to bring forward opportunities from the Group's strategic land portfolio which will add to the quality of the Group's asset platform. We expect local authorities to continue to progress their plans to support growth in housing delivery in line with the National Planning Policy Framework.

 

The Group held cash balances of c. £913m at 31 December 2016 (2015: £570m).

 

We will give a further update on our assessment of the housing market over the early weeks of 2017 when we announce our results for the year ended 31 December 2016 on Monday 27 February 2017.

 

 

Please Note

There will be a call for analysts at 09.00 GMT today. Please use the dial-in details below:

 

Telephone number:

+44(0) 330 336 9105

Conference code:

Persimmon

 

An audiocast of the call will be available on www.corporate.persimmonhomes.com 

 

 

For further information please contact:

 

 

Jeff Fairburn

Group Chief Executive

Mike Killoran

Group Finance Director

 

 

Persimmon Plc

Tel: +44(0)1904 642199

 

 

 

 

Simon Rigby

 

Kevin Smith

 

Jos Bieneman

 

 

 

Citigate Dewe Rogerson

Tel: +44(0) 2076 389571

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGGMNDVGNZM
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.